OverviewSuggest Edit

Boston Scientific Corporation is a developer, manufacturer, and marketer of medical devices. It offers pacemakers, defibrillators, remote patient monitring and diagnostic monitoring solutions, spinal cord stimulator systems, a range of catheters, CTO systems, direct visualization systems, fiducial markers, forceps, guidewires, lasers, fibers, lifting agents, needles, penile prosthesis, retrieval devices, slings, snares, stents, ureterosopes, vein ablation solutions, thrombectomy systems, sphincterotomes, etc.
TypePublic
Founded1979
HQMarlborough, MA, US
Websitebostonscientific.com
Employee Ratings4.3
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2019)36,000(+13%)
Job Openings1
Revenue (FY, 2019)$10.7 B(+10%)
Share Price (Mar 2021)$38.9
Cybersecurity ratingCMore

Key People/Management at Boston Scientific

Michael F. Mahoney

Michael F. Mahoney

Chairman, Chief Executive Officer
Daniel J. Brennan

Daniel J. Brennan

Executive Vice President and Chief Financial Officer
Desiree Ralls-Morrison

Desiree Ralls-Morrison

Senior Vice President, General Counsel and Corporate Secretary
Edward MacKey

Edward MacKey

Executive Vice President, Global Operations
Art Butcher

Art Butcher

Executive Vice President and President, Asia Pacific
Wendy Carruthers

Wendy Carruthers

Senior Vice President, Human Resources
Show more

Boston Scientific Office Locations

Boston Scientific has offices in Marlborough, Arden Hills, Maple Grove, San Jose and in 22 other locations
Marlborough, MA, US (HQ)
300 Boston Scientific Way, Marlborough
Arden Hills, MN, US
4100 Hamline Ave N
Maple Grove, MN, US
1 Scimed Pl
San Jose, CA, US
150 Baytech Dr
Santa Clarita, CA, US
25155 Rye Canyon Loop, Valencia
Spencer, IN, US
780 Brookside Dr
Show all (28)

Boston Scientific Financials and Metrics

Boston Scientific Revenue

Embed Graph
View revenue for all periods
Boston Scientific's revenue was reported to be $10.74 b in FY, 2019 which is a 9.3% increase from the previous period.
USD

Revenue (Q3, 2020)

2.7b

Gross profit (Q3, 2020)

1.8b

Gross profit margin (Q3, 2020), %

67.3%

Net income (Q3, 2020)

(155.0m)

EBIT (Q3, 2020)

(205.0m)

Market capitalization (1-Mar-2021)

55.1b

Closing stock price (1-Mar-2021)

38.9

Cash (30-Sept-2020)

2.0b

EV

62.4b
Boston Scientific's current market capitalization is $55.1 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

9.0b9.8b10.7b

Revenue growth, %

8%9%9%

Cost of goods sold

2.6b2.8b3.1b

Gross profit

6.5b7.0b7.6b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

2.4b2.5b2.4b2.5b2.6b2.7b2.5b2.0b2.7b

Cost of goods sold

672.0m739.0m672.0m730.0m758.0m777.0m806.0m791.0m869.0m

Gross profit

1.7b1.8b1.7b1.8b1.9b1.9b1.7b1.2b1.8b

Gross profit Margin, %

72%70%72%71%71%71%68%61%67%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

188.0m146.0m217.0m

Accounts Receivable

1.5b1.6b1.8b

Inventories

1.1b1.2b1.6b

Current Assets

3.8b4.0b4.7b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

287.0m208.0m168.0m139.0m123.0m277.0m370.0m1.7b2.0b

Accounts Receivable

1.6b1.6b1.6b1.6b1.7b1.8b1.6b1.5b1.6b

Prepaid Expenses

925.0m894.0m

Inventories

1.1b1.1b1.1b1.2b1.3b1.6b1.6b1.5b1.5b
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

104.0m1.7b4.7b(82.0m)

Depreciation and Amortization

844.0m894.0m1.0b1.1b

Inventories

(107.0m)(83.0m)(290.0m)(65.0m)

Accounts Payable

195.0m(631.0m)111.0m88.0m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

298.0m853.0m1.3b424.0m578.0m704.0m11.0m

Cash From Operating Activities

193.0m(210.0m)291.0m350.0m642.0m1.1b(77.0m)192.0m835.0m

Purchases of PP&E

(60.0m)(134.0m)(210.0m)(63.0m)(154.0m)(275.0m)(100.0m)(168.0m)(217.0m)

Cash From Investing Activities

(173.0m)(664.0m)(1.3b)(410.0m)(1.0b)(5.0b)(76.0m)(135.0m)(264.0m)
USDFY, 2017

Revenue/Employee

312.0k

Debt/Equity

0.5 x

Debt/Assets

0.2 x

Financial Leverage

2.7 x
Show all financial metrics

Boston Scientific Operating Metrics

FY, 2017FY, 2018FY, 2019

Countries

125 130 120

Medical Institutions Covered (U.S.)

36 k35 k37 k

Patent Applications

6 k5 k6 k

Patents Issued

19 k19 k21 k
Show all operating metrics

Boston Scientific Acquisitions / Subsidiaries

Company NameDateDeal Size
VertiFlexMay 09, 2019$465 m
BTGNovember 19, 2018$4.20 b
AugmenixSeptember 10, 2018$600 m
VenitiAugust 08, 2018$160 m
Claret MedicalJuly 20, 2018$270 m
Cryterion MedicalJuly 05, 2018
nVision MedicalApril 12, 2018$275 m
Securus Medical GroupApril 03, 2018
NxTheraMarch 21, 2018$306 m
EMcisionMarch 05, 2018
Show more

Boston Scientific Revenue Breakdown

Embed Graph

Boston Scientific revenue breakdown by business segment: 30.8% from MedSurg, 29.2% from Rhythm Management, 39.2% from Cardiovascular and 0.8% from Other

Boston Scientific revenue breakdown by geographic segment: 57.4% from U.S. and 42.6% from Other Countries

Boston Scientific Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

Boston Scientific Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Boston Scientific Online and Social Media Presence

Embed Graph

Boston Scientific Company Culture

  • Overall Culture

    A+

    78/100

  • CEO Rating

    A+

    87/100

  • Compensation

    A+

    83/100

  • Diversity

    B+

    74/100

Learn more on Comparably

Boston Scientific News and Updates

Henry Schein Likely To Offer Better Returns Compared To Boston Scientific Stock

We think that ​Henry Schein currently is a better pick compared to Boston Scientific. HSIC stock trades at about 0.9x trailing Revenues, compared to around 5.5x for Boston Scientific. Does this gap in Henry Schein valuation make sense? While Boston Scientific’s business has been impacted in 2020...

Global $4.7 Billion Erectile Dysfunction Market Outlook and Forecast 2021-2026: Major Players are Eli Lilly and Co, VIVUS, Pfizer, Bayer, Boston Scientific, Coloplast, Teva, Viatris, Dong-A Socio

Dublin, Feb. 23, 2021 (GLOBE NEWSWIRE) -- The "Erectile Dysfunction Market - Global Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global erectile dysfunction is expected to cross $4.7 billion during the period 2021-2026.The global erectile dysfunct…

Boston Scientific Announces February and March 2021 Conference Schedule

MARLBOROUGH, Mass., Feb. 12, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On February 25, 2021, Dan Brennan, executive vice president and chief financial officer, and Susie Lisa, vice president, Investor Relations,...

Global Transcatheter Treatment: Procedures and Heart Valve Market (2020 to 2025) - Featuring Biotronik, Boston Scientific and Bracco Among Others

Dublin, Feb. 11, 2021 (GLOBE NEWSWIRE) -- The "Transcatheter Treatment: Procedures and Heart Valve Market" report has been added to ResearchAndMarkets.com's offering.

Boston Scientific stock falls after profit and sales miss, downbeat outlook

Shares of Boston Scientific Corp. dropped 3.2% in premarket trading Wednesday, after the medical technology company reported fourth-quarter profit and revenue that fell more than expected, and provided a downbeat first-quarter outlook. Net income fell to $138 million, or 10 cents a share, from $4.0…
Show more

Boston Scientific Blogs

Boston Scientific Launches WaveWriter Alpha™ Spinal Cord Stimulator Systems In U.S.

SCS portfolio features largest portfolio of full-body MRI conditional devices that combine therapy options for personalized pain relief

Boston Scientific Receives FDA Approval for the Ranger™ Drug-Coated Balloon

Company provides physicians with first portfolio comprised of drug-eluting stent and drug-coated balloon for the treatment of patients with peripheral artery disease

Boston Scientific Initiates Trial to Evaluate WATCHMAN FLX™ Left Atrial Appendage Closure Device as First-Line Treatment for People at Risk of Stroke

Trial to study next-generation device as treatment alternative to NOACs for broader population of patients with non-valvular atrial fibrillation

Boston Scientific Launches WaveWriter Alpha™ Spinal Cord Stimulator Systems In Europe

SCS portfolio features full-body MRI conditional devices that combine therapy options for personalized pain relief
Show more

Boston Scientific Frequently Asked Questions

  • When was Boston Scientific founded?

    Boston Scientific was founded in 1979.

  • Who are Boston Scientific key executives?

    Boston Scientific's key executives are Michael F. Mahoney, Daniel J. Brennan and Desiree Ralls-Morrison.

  • How many employees does Boston Scientific have?

    Boston Scientific has 36,000 employees.

  • What is Boston Scientific revenue?

    Latest Boston Scientific annual revenue is $10.7 b.

  • What is Boston Scientific revenue per employee?

    Latest Boston Scientific revenue per employee is $298.2 k.

  • Who are Boston Scientific competitors?

    Competitors of Boston Scientific include Merit Medical Systems, Integer Holdings and Johnson & Johnson.

  • Where is Boston Scientific headquarters?

    Boston Scientific headquarters is located at 300 Boston Scientific Way, Marlborough, Marlborough.

  • Where are Boston Scientific offices?

    Boston Scientific has offices in Marlborough, Arden Hills, Maple Grove, San Jose and in 22 other locations.

  • How many offices does Boston Scientific have?

    Boston Scientific has 28 offices.